Lung treatment firm Pulmonx's Q3 revenue up 5%, net loss narrows marginally

Pulmonx

12/11/2025 21:41

Overview

Pulmonx Q3 2025 revenue rises 5% yr/yr to $21.5 mln

International revenue grows 15% yr/yr, U.S. revenue up 1%

Pulmonx reports Q3 net loss of $14 mln, marginally lower than last year

Outlook

Pulmonx expects 2025 revenue between $89 mln and $90 mln

Company anticipates 2025 gross margin of approximately 73%

Pulmonx forecasts 2025 operating expenses of $125 mln to $126 mln

Result Drivers

INTERNATIONAL REVENUE GROWTH - Driven by global adoption of Zephyr Valve procedures

ZEHPYR VALVE ADOPTION - Co attributes revenue growth to continued commercial execution and global adoption of Zephyr Valve procedures

OPERATING EXPENSES - Increase in operating expenses due to clinical, development, and commercial investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.34
Q3 Net Income
-$13.96 mln
Q3 Gross Profit
$16.05 mln
Q3 Income From Operations
-$14.39 mln
Q3 Pretax Profit
-$13.83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Pulmonx Corp is $4.50, about 53.6% above its November 11 closing price of $2.09

Press Release: ID:nGNX8k5bW8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)